Head to Head Review: Celcuity (NASDAQ:CELC) vs. Sernova Biotherapeutics (OTCMKTS:SEOVF)

Celcuity (NASDAQ:CELC) and Sernova Biotherapeutics (OTCMKTS:SEOVF) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Volatility and Risk

Celcuity has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Sernova Biotherapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Celcuity and Sernova Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-150.07%	-64.67%
Sernova Biotherapeutics	N/A	N/A	-396.49%

Earnings and Valuation

This table compares Celcuity and Sernova Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$111.78 million	($3.45)	-14.85
Sernova Biotherapeutics	N/A	N/A	-$23.65 million	($0.04)	-3.28

Celcuity is trading at a lower price-to-earnings ratio than Sernova Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

63.3% of Celcuity shares are held by institutional investors. 15.8% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Celcuity and Sernova Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	0	0	4	0	3.00
Sernova Biotherapeutics	0	0	0	0	0.00

Celcuity currently has a consensus target price of $56.50, indicating a potential upside of 10.29%. Given Celcuity’s stronger consensus rating and higher probable upside, equities analysts clearly believe Celcuity is more favorable than Sernova Biotherapeutics.

Summary

Celcuity beats Sernova Biotherapeutics on 6 of the 11 factors compared between the two stocks.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

About Sernova Biotherapeutics

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.